Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Phase 2 N=58 Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival at 6 Months. — 39; 6 Participants
Phase 2 N=23 A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 2 N=136 Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
N/A N=66 Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Phase 2 N=75 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 2 N=38 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Phase 2 N=65 PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Pediatric Recurrent Progressive Low-grade Gliomas · Pediatric Progressive Low-grade Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months — 67 percentage
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Phase 2 N=64 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Glioblastoma · Gliosarcoma
Primary: 12-month Progression Free Survival (PFS) — 43.8; 34.4 percentage of participants
Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Phase 2 N=23 Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
Glioma · Low-grade Glioma · Astrocytoma
Primary: Overall Response — 2; 21 participants
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Phase 2 N=25 TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Astrocytoma
Primary: Progression Free Survival at 6 Months (PFS6) — 47 percentage of participants
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=118 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Phase 1 N=9 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
N/A N=20 Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma
Low Grade Gliomas
Primary: Number of Participants With Late Effects > 3 Months Post RT — 20 Participants
Phase 2 N=41 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Glioblastoma · Gliosarcoma
Primary: Response Rate — 24.4 percentage of patients
Phase 2 N=31 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM
Glioblastoma Multiforme · Brain Tumor
Primary: Progression-free Survival (PFS) — 91.3 percentage of participants
Phase 2 N=85 Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
Glioblastoma · Gliomas
Primary: 12 Month Overall Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concurrent Temozolomide and Radiotherapy Followed by Dose Dense or…
Phase 2 N=11 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Safety of Twice a Day Oral 150 mg Erlotinib Dosing — 9 participants
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 1 N=24 IDH1 Peptide Vaccine for Recurrent Grade II Glioma
Brain Cancer · Brain Neoplasm, Primary · Brain Neoplasms, Recurrent
Primary: Percentage of Participants With an Unacceptable Toxicity — 0 percentage of participants